Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1969 results about "Staphylococcus bacteria" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A staphylococcal infection is a common bacterial skin infection. Staphylococci (‘staph’) are a common type of bacteria that live on the skin and mucous membranes (for example, in the nostrils) of humans. Staphylococcus aureus (S aureus) is the most important of these bacteria in human diseases.
Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
ActiveUS20100074872A1Growth inhibitionFacilitate calorie uptakeBiocideMetabolism disorderBacteroidesDisease
The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.
Owner:NEW YORK UNIV
Nanosilver-containing antibacterial and antifungal granules and methods for preparing and using the same
Owner:LEGEND WIN FINANCE
Enterococcus faecium ANSE228 and application thereof
ActiveCN102031235AIncrease production capacityReduce the death rateAntibacterial agentsBacteriaEscherichia coliStaphylococcus cohnii
The invention provides an Enterococcus faecium ANSE228 of which the collection number is CGMCC No.4082. The invention also provides application of the Enterococcus faecium ANSE228 to inhibition of salmonella pullorum and / or Escherichia coli and / or Staphylococcus aureus. The Enterococcus faecium ANSE228 is obtained by processes of repeated separation, purification, rejuvenation and the like, and has high biological activity, obvious probiotic property, high adversity resistance and the like. The invention also provides a microecological agent which contains the Enterococcus faecium ANSE228. When the microecological agent is added into drinking water and / or feeds for breeding animals, the Enterococcus faecium ANSE228 can be quickly activated and reproduced and a dominant beneficial flora can be formed after the Enterococcus faecium ANSE228 is fed into intestinal canals of the animals, and the Enterococcus faecium ANSE228 has the effects of reducing a harmful flora in the intestinal canals, adjusting microecological balance of the intestinal canals, substituting for medicaments such as antibiotic and the like, and improving weight increment of the animals and the utilization rate of the feeds.
Owner:科润生科技发展有限公司
Compositions and methods related to protein a (SPA) variants
ActiveUS20120114686A1Reduced activityPrevents alleviates ameliorates symptomAntibacterial agentsBacterial antigen ingredientsStaphylococcus xylosusProtein A
Disclosed are methods and compositions for treating or preventing a Staphylococcus bacterial infection using a non-toxigenic Protein A (SpA) variant.
Owner:UNIVERSITY OF CHICAGO
Staphylococcus antigen and vaccine
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Use of alpha-toxin for treating and preventing staphylococcus infections
InactiveUS20090053235A1Low toxicityAntibacterial agentsBacterial antigen ingredientsBacteroidesAlpha-toxin
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Biological denitrification method for salt-containing sewage
ActiveCN103373762AEasy to transportDoes not affect activityWater contaminantsTreatment with aerobic and anaerobic processesStaphylococcus cohniiChemical oxygen demand
The invention relates to a biological denitrification method for salt-containing sewage, which comprises the following steps: adding a denitrification microbial inoculant into a biochemical sewage treatment system, and simultaneously starting the nitrification-denitrification biological denitrification treatment processes, wherein the sewage treatment temperature is 18-40 DEG C, the dissolved oxygen is 0.1-5 mg / L, and the pH value is 7.0-9.0. The denitrification microbial inoculant contains one or two of Staphylococcuscohnii FSDN-C, Arthrobactercreatinolyticus FDN-1 and Flavobacteriummizutaii FDN-2, and also contains one or two of Paracoccusdenitrificans DN-3 and Methylobacteriumphyllosphaerae SDN-3. The method provided by the invention can effectively treat high-salt-content sewage, enhances the adsorptivity and flocculence for sludge, has wide application range for wastewater quality and high impact resistance to salt-containing sewage, and obviously enhances the sewage treatment effect on the premise of removing pollutants, such as ammonia nitrogen, COD (chemical oxygen demand) and the like.
Owner:CHINA PETROLEUM & CHEM CORP +1
Traditional Chinese medicine inclusion compound with antibacterial effect and textile finishing method of traditional Chinese medicine inclusion compound
InactiveCN102605630AImprove the immunityOvercome the single defect of antibacterial effectFibre treatmentBiotechnologyCyclodextrin
The invention discloses a traditional Chinese medicine inclusion compound with an antibacterial effect and a textile finishing method of the traditional Chinese medicine inclusion compound. The traditional Chinese medicine inclusion compound is prepared from traditional Chinese medicine extract liquid with the total ingredient percentage being 100 percent and beta-cyclodextrin through a saturated water solution method, wherein the traditional Chinese medicine extract liquid comprises the following ingredients in percentage by mass: 25 percent to 60 percent of honeysuckle, 15 percent to 50 percent of folium Artemisiae argyi, 20 percent to 35 percent of liquorice and 5 percent to 15 percent of scutellaria baicalensis. The traditional Chinese medicine inclusion compound and cross linking agents are added into chitosan acetic acid solution to be prepared into antibacterial finishing liquid. A simple rolling baking process is adopted for carrying out antibacterial finishing on the cellulose fiber, the process is simple, the finished textile has the broad-spectrum antibacterial performance on common germs such as staphylococcus aureus, escherichia coli and the like, and in addition, the water washing resistance performance is good.
Owner:NANTONG JIAYUSI TEXTILE GROUP
Use of alpha-toxin for treating and preventing staphylococcus infections
InactiveUS20080131457A1Low toxicityAntibacterial agentsBacterial antigen ingredientsBacteroidesAlpha-toxin
Vaccines comprising an S. aureus alpha-toxin antigen and a pharmaceutically acceptable carrier are provided, and are useful for treating and preventing infections. The S. aureus alpha-toxin antigen may contain at least two alterations that reduce its toxicity and / or may be conjugated to or co-administered with another bacterial antigen. The vaccines may comprise one or more other bacterial antigens. Antibody compositions comprising antibodies to alpha-toxin and optionally one or more other bacterial antigens also are provided, and are useful for treating and preventing infections.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
ActiveUS20110274693A1Reduce in quantityReduce severityAntibacterial agentsPeptide/protein ingredientsPhagocyteWhite blood cell
Disclosed herein are isolated and purified Staphylococcus aureus bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and / or LukB, or anti-LukA and / or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions or S. aureus infection, methods for identifying inhibitors of LukAB-mediated cytotoxicity of human phagocytes, and methods for using LukAB as a marker to predict severity of S. aureus infection.
Owner:NEW YORK UNIV
Synergistic acidic ternary biocidal compositions
InactiveUS20060293214A1Great anti-microbial activitySurprising synergistic antimicrobial efficacyBiocideAnionic surface-active compoundsBiotechnologySalmonella kiel
Aqueous dilutions of acidic ternary compositions having unusually synergistic antimicrobial activity against Staphylococcus aureus and Salmonella choleraesuis microorganisms are disclosed. The compositions encompass ternary component mixtures of an alpha-hydroxycarboxylic acid, a monohydric water soluble alkanol and an anionic tenside having a Ternary Ratio residing within a defined phase region wherein synergistic antimicrobial activity is observed; whereas mixtures outside of the defined phase region and those lacking any one of the components do not exhibit synergistic activity. Compositions, methods and articles employing the inventive ternary synergistic compositions, and their utility in sanitizing and disinfecting hard surfaces are described.
Owner:THE CLOROX CO
Enterococcus faecium ANSE228 and application thereof
ActiveCN102031235BSignificant probioticInhibition of growth and reproductionAntibacterial agentsBacteriaBiotechnologyStaphyloccocus aureus
The invention provides an Enterococcus faecium ANSE228 of which the collection number is CGMCC No.4082. The invention also provides application of the Enterococcus faecium ANSE228 to inhibition of salmonella pullorum and / or Escherichia coli and / or Staphylococcus aureus. The Enterococcus faecium ANSE228 is obtained by processes of repeated separation, purification, rejuvenation and the like, and has high biological activity, obvious probiotic property, high adversity resistance and the like. The invention also provides a microecological agent which contains the Enterococcus faecium ANSE228. When the microecological agent is added into drinking water and / or feeds for breeding animals, the Enterococcus faecium ANSE228 can be quickly activated and reproduced and a dominant beneficial flora can be formed after the Enterococcus faecium ANSE228 is fed into intestinal canals of the animals, and the Enterococcus faecium ANSE228 has the effects of reducing a harmful flora in the intestinal canals, adjusting microecological balance of the intestinal canals, substituting for medicaments such as antibiotic and the like, and improving weight increment of the animals and the utilization rate of the feeds.
Owner:科润生科技发展有限公司
N-thiolated beta-lactams: novel antibacterial agents for methicillin-resistant Staphylococcus aureus
The invention relates generally to novel N-thiolated β-lactams. More specially, the invention relates to the use of these novel antibacterial agents in the treatment or inhibition of methicillin-resistant Staphylococcus aureaus.
Owner:SOUTH FLORIDA UNIVESITY OF
Carbacephem beta-lactam antibiotics
InactiveUS20050004095A1Antibacterial agentsOrganic active ingredientsAntibiotics beta lactamBeta lactam antibiotics
The present invention relates to carbocephem antibiotics and pharmaceutically acceptable salts thereof useful for the treatment of bacterial infections, in particular infections caused by methicillin-resistant Staphylococcus spp. bacteria.
Owner:TRINE PHARMA
Human Binding Molecules Having Killing Activity Against Staphylococci and Uses Thereof
ActiveUS20090104204A1Avoid adjustmentInhibiting and reducing spread of StaphylococcusAntibacterial agentsSugar derivativesGenus staphylococcusMolecular biology
The present invention provides human binding molecules specifically binding to staphylococci and having killing activity against staphylococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and / or treatment of a condition resulting from Staphylococcus.
Owner:JANSSEN VACCINES & PREVENTION BV
Sequences for detection and identification of methicillin-resistant Staphylococcus aureus (MRSA) of MREJ types xi to xx
Described herein are novel SCCmec right extremity junction (MREJ) sequences for the detection and / or identification of methicillin-resistant Staphylococcus aureus (MRSA). Disclosed are methods and compositions based on DNA sequences for the specific detection of MREJ sequences designated types xi, xii, xiii, xiv, xv, xvi, xvii, xviii, xix, and xx for diagnostic purposes and / or epidemiological typing.
Owner:GENEOHM SCI INC
Method for preparing nanofibre membrane
InactiveCN101638830AHas antibacterial functionPromote wound healing functionFilament/thread formingAbsorbent padsComposite nanofibersNanofiber
The invention discloses a method for preparing a nanofibre membrane, belonging to a technique for preparing a nanofibre compound membrane. The method comprises the following steps: preparing curcuminethanol solution and chitosan acetum, mixing the curcumin ethanol solution and the chitosan acetum by the volume ratio thereof to prepare spinning solution which is injected into an injector of an electrostatic spinning device for electrostatic spinning to form a compound nanofibre membrane and to obtain a curcumin / chitosan nanofibre membrane of antibacterial property, wherein the diameter of thecurcumin / chitosan nanofibre membrane is 200-400 nm. The invention has the advantages that the preparation process is simple, the prepared membrane material heals wound, has broad spectrum bactericidalproperty and has higher bacterial inhibition rate to colibacillus and staphylococcus aureus for 24h.
Owner:JIANGNAN UNIV +1
Nano-silver loaded activated carbon fiber and preparation method thereof
InactiveCN106958140AEvenly dispersedSmall diameterCarbon fibresFiltration separationActivated carbonStearic acid
The invention discloses a nano-silver loaded activated carbon fiber and a preparation method thereof. The preparation method comprises the following steps: (1) taking AgNO3 or CH3COOAg as a silver source; (2) utilizing a mixed solution of stearic acid, lauric acid and polyvinylpyrrolidone as a protecting agent; (3) taking the mixed solution of glycol, formaldehyde and glucose as a reducing agent; (4) fully dipping an activated carbon fiber in the AgNO3 or CH3COOAg solution, thereby loading silver ions on the surface of the activated carbon fiber; and (5) in an acetone system, utilizing the reducing agent to reduce the silver ions on the surface of the activated carbon fiber, thereby generating nano-silver particles on the surface of the activated carbon fiber. The product disclosed by the invention is characterized by adjustable silver loading capacity, monomer silver particle diameter of 10-20 nanometers, application to the filtering and sterilizing technology for drinking water and efficient function of killing escherichia coli and staphylococcus aureus in water. Besides, the nano-silver loaded activated carbon fiber has higher application value in improving water chrominance and turbidity and reducing residual chlorine in water.
Owner:北京璟胜科技有限公司
Human binding molecules having killing activity against staphylococci and uses thereof
ActiveUS8211431B2Increase opportunitiesProper fluidityAntibacterial agentsSugar derivativesMicrobiologyMolecular biology
The present invention provides human binding molecules specifically binding to staphylococci and having killing activity against staphylococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and / or treatment of a condition resulting from Staphylococcus.
Owner:JANSSEN VACCINES & PREVENTION BV
Nano-silver antibacterial melt-blown non-woven fabric and production method thereof
ActiveCN104047114AHigh strengthAvoid breakingFilament forming substance formingArtificial thread manufacturing machinesPolyesterNonwoven fabric
The invention relates to nano-silver antibacterial melt-blown non-woven fabric and a production method thereof. The nano-silver antibacterial melt-blown non-woven fabric is characterized in that the fabric contains hybrid nanoscale antibacterial powder, a non-woven fabric base stock can be polypropylene, polyester or polyphenylene sulfide, the hybrid nanoscale antibacterial powder is formed in a way that nanoscale zirconium phosphate and silver nitrate are exchanged in water to form silver phosphate, zinc oxide needs to be added in the exchange process, and the antibacterial powder has the proportion of ingredients as follows: 2-5 percent of the silver nitrate, 90-95 percent of the zirconium phosphate and 1-5 percent of the zinc oxide. The nano-silver antibacterial melt-blown non-woven fabric has excellent inhibition and stop effects on escherichia coli, staphylococcus aureus, Candida albicans and the like, and can filter various particles with the pm (particulate matter) over 2.5 in current air haze, the filter efficiency is over 95 percent, and the antibacterial ratio is over 99 percent; the fabric is tested by sgs (Societe Generale de Surveillance); the prepared nano-silver antibacterial melt-blown non-woven fabric is good in strength, not easy to break, soft and comfortable.
Owner:李文博 +1
Composite antibiotic finishing agent and preparation method and finishing process thereof for application to mucilage glue and cotton fiber interweaved jacquard fabric
The invention discloses a composite antibiotic finishing agent which comprises an organic antibacterial active component, an inorganic antibacterial active component, a penetrating agent, an adhesive, a softening agent, a suspending agent and the balance of water, wherein a non-dissolution type polymer antibacterial agent is selected as the organic antibacterial active component, and silver-loaded nanometer titanium dioxide is selected as the inorganic antibacterial active component. The invention also discloses a method for preparing the composite antibiotic finishing agent and a process used for finishing a mucilage glue and cotton fiber interweaved jacquard fabric. The main material of the composite antibiotic finishing agent for textiles is formed by the organic antibacterial active component and the inorganic antibacterial active component, thus the composite antibiotic finishing agent has a high-efficiency inhibiting capacity of more than 20 kinds of harmful bacteria such as escherichia coli, staphylococcus aureus, gonococcus and the like; the bacteria inhibiting rate is higher than 99 percent; the repelling and preventing rate of dust mites, gamasid mites and chigger is higher than 99 percent; the repelling and preventing rate of dust mites, gamasid mites and chigger is higher than 95 percent, and the killing rate is higher than 90 percent after the mucilage glue and cotton fiber interweaved jacquard fabric is washed for 50 times; and the gonococcus, escherichia coli, staphylococcus aureus and the like do not grow on the fabric which is not washed for 30 times, 50 times or 100 times, and the bacteria inhibiting rate is higher than 99 percent.
Owner:SHANGHAI SHUIXING HOME TEXTILE
Methods and Compositions for the Prevention of and Treatment of Infections Utilizing Chitosan-Derivative Compounds
The present invention is directed to the treatment and prevention of nosocomial infections or MRSA infections utilizing soluble chitosan or chitosan derivative compounds. These chitosan-derivative compounds, e.g., chitosan-arginine and chitosan-acid amines, exhibit bactericidal activity against bacterial pathogens, e.g., drug resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA).
Owner:SYNEDGEN
N, P and S-codoped fluorescent carbon quantum dot and preparation method and application thereof
InactiveCN105567228AEasy to operateWide variety of sourcesNanoopticsFluorescence/phosphorescenceEscherichia coliFreeze-drying
The invention provides an N, P and S-codoped fluorescent carbon quantum dot and a preparation method and application thereof, and belongs to the technical field of luminescent nanomaterials. The preparation method comprises the steps that a biological bacterium (saccharomycete or escherichia coli or staphylococcus aureus or aspergillus niger) is taken as a carbon source, water of the corresponding volume is added, and a hydrothermal reaction is performed to obtain a dark brown solution; after the reaction stops and a reaction kettle is naturally cooled, dialysis is performed to remove impurities, an aqueous carbon quantum dot solution is obtained, and after freeze drying is performed, the N, P and S-codoped fluorescent carbon quantum dot is obtained. According to the method, the biomass is taken as the carbon source, the raw material is wide in source, low in cost, green and environmentally friendly, the technology is simple, and the preparation condition requirement is low. The obtained carbon quantum dot can be applied to detection on Cr (VI) ions, MnO4<-> and ascorbic acid by serving as a switch-type fluorescent probe and also can be used for cell imaging.
Owner:SHANXI UNIV
Antibacterial fabric finishing agent containing chitose its production and usage
InactiveCN101074541AIncrease anchorageImprove antibacterial propertiesFibre treatmentAcetic acidEscherichia coli
One finishing solution of fabrics containing chitosan is composed of Chitosan (MW <= 5000, the degree of deacetylation of >= 90%, 1.00 - 5.00%), acetic acid (0.50 - 6.00%), epichlorohydrin (0.01 - 1.00%) and water. The process for the fabric finishing is: I,fabric Pretreatment: fabric by the alkali treatment (8 - 11% NaOH at room temperature), washed, acid and (2 - 4% acetic acid at room temperature), drying (85 - 100 deg.C). II,finishing: baptist, rolling (room temperature, 15 to 25 min, rolling rate of more than 80 - 90%), alkali (room temperature, 5 - 8% NaOH), acid and (room temperature, 1 to 3% acetic acid) and Drying (85 - 100 deg.C). The test results show that the inhibitory rate for staphylococcus aureus, Escherichia coli, Streptococcus white Nian is more than 99% which is the higher level compared to the state 3-A class standard. The fastness of fabrics reaches 4 after washing.
Owner:大连利健甲壳素股份有限公司
Compositions for immunising against staphylococcus aureus
ActiveUS20120093850A1Reduce and eliminate haemolytic activityAntibacterial agentsHydrolasesMicrobiologyStaphyloccocus aureus
Staphylococcus aureus Hla polypeptides having various deletions, insertions, and / or mutations which are useful for immunisation are provided herein. Also provided herein are Hla heptamers which are non-haemolytic. Additionally, an effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens, including Hla polypeptides having deletions, insertions, and / or mutations, are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Compositions and methods related to antibodies to staphylococcal protein a
ActiveUS20140170134A1Reduced activityReduce bacterial loadAntibacterial agentsCompound screeningMicrobiologyBiochemistry
Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Staphylococcal protein A (SpA).
Owner:UNIVERSITY OF CHICAGO
Novel aminoglycoside antibiotics effective against methicillin resistant staphylococcus auerus (mrsas)
InactiveUS20070161581A1Great anti-microbial activitySignificant antimicrobial activityAntibacterial agentsBiocideMethicillin resistant StaphylococcusGlycoside
Disclosed are compounds represented by general formula (I) or pharmacologically acceptable salts or solvates thereof having excellent antimicrobial activity against bacteria causative of severe infections such as pneumonia and septicemia, particularly against MRSA, and also antimicrobial agents comprising these compounds, and pharmaceutical compositions comprising these compounds as an active component.
Owner:MEIJI SEIKA KAISHA LTD +1
Polyhexamethylene guanidine propionate disinfectant and preparation method thereof
InactiveCN101574087AImprove the bactericidal effectEnhance long-term antibacterial effectBiocideDead animal preservationEscherichia coliNon toxicity
The invention provides a polyhexamethylene guanidine propionate disinfectant and a preparation method thereof. The polyhexamethylene guanidine propionate disinfectant is a hydrophilic solution prepared by the following steps: adding polyhexamethylene guanidine propionate, citric acid and surfactant to water and uniformly stirring the mixture at normal temperature. The polyhexamethylene guanidine propionate disinfectant has the advantages of broad spectrum of disinfection, quick results, long-time disinfection capability, high safety, non-toxicity, environmental protection, high stability, easy application, quick infiltration and volatilization, no coloration, easy cleaning, and the like. The polyhexamethylene guanidine propionate disinfectant has strong sterilization functions for colon bacillus, staphylococcus aureus, candida albicans, and the like with two-year effective periods. The polyhexamethylene guanidine propionate disinfectant can be used for disinfection of skins, wound surfaces, hands, air, departments of gynecology and urology, drinking water, and the like, thereby being a novel and ideal disinfectant.
Owner:铜陵高聚生物科技有限公司
Specific antibacterial PE (polyethylene) preservative film
The invention relates to a PE (polyethylene) preservative film containing glass-carrier silver-ion antibacterial agent. An ordinary PE (polyethylene) preservative film contains 0.05 percent to 1 percent of glass-carrier silver-ion antibacterial agent, or further contains one or more of 0.1 percent to 1.5 percent of tackifier, 1 percent to 5 percent of antifogging agent and 0.05 percent to 0.4 percent of edible oil, and the PE in the PE (polyethylene) preservative film is low-density polyethylene or linear low-density polyethylene, or the mixture of low-density polyethylene and linear low-density polyethylene according to a certain proportion. In the preparation technique, the PE polyethylene and the glass-carrier silver-ion antibacterial agent are mixed and pelleted by a single-screw or double-screw extruder, so that antibacterial masterbatches are produced. The extruder then produces the antibacterial preservative film according to the formula by way of casting or film blowing. The product has a high antibacterial property and is durable, and the color cannot be easily changed. In particular, the preservative film has excellent inhibiting and sterilizing effects on bacteria such as colibacillus and staphylococcus aureus.
Owner:陈迦乐
Plant bacteriostatic composition and application thereof in cosmetics
ActiveCN102669191AGood antibacterial effectAdd lessCosmetic preparationsBiocideEscherichia coliOfficinalis
The invention provides a plant bacteriostatic composition and application thereof in cosmetics. The plant bacteriostatic composition is obtained by compounding a licorice extract, a honeysuckle extract and a Mangnolia officinalis extract. The plant bacteriostatic composition has good bacteriostatic effect and particularly has a synergistic effect of inhibiting escherichia coli, staphylococcus aureus, pseudomonas aeruginosa, candida albicans and aspergillus niger. The plant bacteriostatic composition can be applied to skin-care and washing cosmetics, reduces the adding amount of original preservatives and enables a product to have both antibacterial and anti-inflammatory effects.
Owner:TIANJIN YU MEI JING GRP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com